Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CRDL - Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis

CRDL - Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis

Cardiol Therapeutics Inc.

(NewsDirect)

Cardiol Therapeutics CEO David Elsley shared news the company hashit a major milestone in that the first patient has been enrolled in aPhase II open-label pilot study of CardiolRx in patients withrecurrent pericarditis. Elsley told Proactive the study is designed toevaluate improvement in objective measures of disease and assess thefeasibility of weaning concomitant background therapy includingcorticosteroids, while taking CardiolRx. The study is expected toenroll 25 patents.

ProactiveCanada Financial News

ContactDetails

Proactive Canada

ProactiveCanada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Cardiol Therapeutics Inc.
Stock Symbol: CRDL
Market: NASDAQ
Website: cardiolrx.com
Menu
CRDL CRDL Quote CRDL Short CRDL News CRDL Articles CRDL Message Board
Get CRDL Alerts

News, Short Squeeze, Breakout and More Instantly...